Navigation Links
New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
Date:8/31/2007

dications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that targets two receptors located in the brain's suprachiasmatic nucleus (SCN). The SCN is known as the body's "master clock" because it regulates the sleep- wake cycle. *ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking ROZEREM with alcohol.

ROZEREM has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. ROZEREM should not be taken with or immediately after a high-fat meal. ROZEREM should be taken within 30 minutes before going to bed and activities confined to preparing for bed.

The most common adverse events seen with ROZEREM that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

For complete Prescribing Information, visit

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  OncoGenex Pharmaceuticals, Inc. ... report its second quarter 2015 financial results on Thursday, ... call and live webcast at 4:30 p.m. Eastern Time ... programs and a general corporate update. ... Relations page of the OncoGenex website at www.oncogenex.com ...
(Date:7/30/2015)... PLAINFIELD, N.J., July 30, 2015 PTC Therapeutics, ... update and reported financial results for the second quarter ... progressing on many fronts across the organization.  We are ... Duchenne muscular dystrophy clinical trial ever conducted with topline ... Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. "Translarna ...
(Date:7/30/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ) ... patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics ... notice it received on May 21, 2015 from the ... was below certain of the Exchange,s continued listing standards, ... the NYSE MKT Company Guide, due to the delay ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10TPI Provides Update Regarding Non-Compliance with NYSE MKT Continued Listing Requirements 2
... MASI ) today announced that its management is scheduled ... The Pierre Hotel in New York on Tuesday, November 15, ... the presentation will be available on the Masimo website at ... available following the live presentation. About ...
... Nov. 8, 2011 ChemoCentryx, Inc., today announced that ... the Annual Meeting of the American College of Rheumatology ... targets and inhibits the chemokine receptor known as CCR1, ... rheumatoid arthritis (RA).  Results showed that CCX354 was safe ...
Cached Medicine Technology:Masimo to Present at Lazard Capital Markets Healthcare Conference 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4
(Date:7/31/2015)... ... July 31, 2015 , ... The 2nd annual Ride to Fight On will ... October 3, 2015. The Ride to Fight On is a cycling fundraiser that benefits ... The West Clinic and The University of Tennessee Health Science Center. A health and ...
(Date:7/31/2015)... ... 31, 2015 , ... Coco Libre announced today that their flagship Organic Coconut ... 2015 Vans US Open of Surfing, July 25 through August 2 in Huntington Beach, ... on the market, is a natural choice given the Open’s commitment to sustainable practices. ...
(Date:7/31/2015)... ... July 31, 2015 , ... Well-known for its unique pastries ... wedding cakes with custom designs, making life just a little bit sweeter for ... cakes for each customer who orders one. , The bakery provides a full line ...
(Date:7/31/2015)... ... 2015 , ... Transfinder, a software company based in Schenectady, N.Y., achieved record ... year-over-year for the first six months ended June 30, 2015 compared with the same ... last year’s record-revenue mark of $10.4 million. , “We know what our customers need ...
(Date:7/31/2015)... NY (PRWEB) , ... July 31, 2015 , ... The ... marijuana, on research projects that evaluate the potential of related, experimental treatments. The collaboration ... Department of Health to award Columbia Care one of five state licenses to produce ...
Breaking Medicine News(10 mins):Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 2Health News:West Cancer Center Announces 2nd Annual Ride to Fight On 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Pastry Palace of Las Vegas Announces It Is Now Offering Custom Wedding Cakes in Las Vegas 2Health News:Transfinder Closes First Half of 2015 with Record Revenue 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 2Health News:Mount Sinai to Collaborate with Columbia Care on Medical Marijuana Research 3
... students to benefit from program targeting kids in five-county ... American dream -- that children have more opportunities and ... at risk as the incidence of obesity among children ... could become the first in this country,s history to ...
... Andre Konski, M.D., M.B.A., has been offered ... Department of Radiation Oncology for the Wayne ... Chief for Radiation Oncology at the Barbara Ann ... Konski comes to Wayne State and ...
... Pierre,s Ice Cream Company, makers of,Hola Fruta!(R) ... innovation,called Yovation(TM). , (Photo: ... Yovation(TM) is a new premium, probiotic frozen ... and popularity of probiotic products and the,recognition by ...
... Plans Thousands of Franchisees Nationally With More than 1,800 ... eMed-ID, the world,s first medical identification franchise, announced today ... provides a personal USB device to consumers containing their ... for consumers to document their private medical history on ...
... Jan. 9 (HealthDay News) -- Parents may not always ... exercise habits, a new study shows. , Researchers reported ... Education and Behavior that mothers of preschool-aged children ... with older children did not. But when the children ...
... enhanced website designed to provide improved accessibility and ... Labs, a Zeus company, announces the launch of ... via the original URL and can be found ... with expanded content, including more information about Polymathic,s ...
Cached Medicine News:Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 2Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 3Health News:The Archdiocese of Philadelphia and Independence Blue Cross Team Up to Address Childhood Obesity 4Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 2Health News:Andre Konski, M.D., M.B.A., Accepts Radiation Oncology Position at Wayne State University and the Karmanos Cancer Institute 3Health News:Standing Ovation for Pierre's New Innovation! 2Health News:Standing Ovation for Pierre's New Innovation! 3Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 2Health News:World's First Medical Identification Franchise Launches at Miami's Franchise Expo South 3Health News:Parents Not Best Barometer of Kid's Eating, Exercise Habits 2Health News:Polymathic Analytical Labs Launches New Website 2
Multipiece PMMA IOL - Sulcus Fixation....
Hydrophilic Acrylic Intraocular Lens (Refractive and Bifocal). Anterior Chamber Lens....
Raysoft Foldable Intraocular Lens....
HAPTIBAG Hydrophilic Acrylic Lens....
Medicine Products: